Outcome of treatment with Hyper-CVAD regimen in Chinese patients with acute lymphocytic leukemia

Leukemia Research

Volumn 32, Issue 6, 2008, Pages 930-935

  Xu, Wei ^a   Li, Jian Yong ^a   Qian, Si Xuan ^a   Wu, Han Xin ^a   Lu, Hua ^a   Chen, Li Juan ^a   Zhang, Su Jiang ^a   Lu, Rui Lan ^a   Sheng, Rui Lan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Acute lymphocytic leukemia; Hyper CVAD regimen; Remission; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FOLINATE CALCIUM; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; MERCAPTOPURINE; MESNA; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CANCER RELAPSE; CANCER SURVIVAL; CHINESE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; FEMALE; FEVER; FOLLOW UP; HEART DISEASE; HEPATOMEGALY; HERPES ZOSTER; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTOSIS; LIVER DYSFUNCTION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MOOD CHANGE; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SPLENOMEGALY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 40749125644     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.10.019     Document Type: Article

References (18)

1. Larson R.A., Dodge R.K., Burns C.P., Lee E.J., Stone R.M., Schulman P., et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85 (1995) 2025-2037
2. Thomas X., Boiron J.M., Huguet F., Dombret H., Bradstock K., Vey N., et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 22 (2004) 4075-4086
3. Annino L., Vegna M.L., Camera A., Specchia G., Visani G., Fioritoni G., et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99 (2002) 863-871
4. Larson R.A. The U.S. trials in adult acute lymphoblastic leukaemia. Ann Hematol 83 Suppl 1 (2004) S127-S128
5. Pui C.H., and Evans W.E. Acute lymphoblastic leukemia. N Engl J Med 339 (1998) 605-615
6. Pui C.H., and Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 354 (2006) 166-178
7. Murphy S.B., Bowman W.P., Abromowitch M., Mirro J., Ochs J., Rivera G., et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 4 (1986) 1732-1739
8. Koller C.A., Kantarjian H.M., Thomas D., O'Brien S., Rios M.B., Kornblau S., et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 11 (1997) 2039-2044
9. Khouri I.F., Romaguera J., Kantarjian H., Palmer J.L., Pugh W.C., Korbling M., et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16 (1998) 3803-3809
10. Thomas D.A., Cortes J., O'Brien S., Pierce S., Faderl S., Albitar M., et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 17 (1999) 2461-2470
11. Kantarjian H.M., O'Brien S., Smith T.L., Cortes J., Giles F.J., Beran M., et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18 (2000) 547-561
12. Cortes J., Thomas D., Rios A., Koller C., O'Brien S., Jeha S., et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 94 (2002) 1492-1499
13. Thomas D.A., O'Brien S., Cortes J., Giles F.J., Faderl S., Verstovsek S., et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104 (2004) 1624-1630
14. Kantarjian H., Thomas D., O'Brien S., Cortes J., Giles F., Jeha S., et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101 (2004) 2788-2801
15. Romaguera J.E., Fayad L., Rodriguez M.A., Broglio K.R., Hagemeister F.B., Pro B., et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23 (2005) 7013-7023
16. Lane S.W., Crawford J., Kenealy M., Cull G., Seymour J.F., Prince H.M., et al. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leuk Lymphoma 47 (2006) 813-1817
17. Hunault M., Harousseau J.L., Delain M., Truchan-Graczyk M., Cahn J.Y., Witz F., et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 104 (2004) 3028-3037
18. Thomas D.A., Faderl S., Cortes J., O'Brien S., Giles F.J., Kornblau S.M., et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103 (2004) 4396-4407